ICH Q11 Development and Manufacture of Drug Substances
E555153
ICH Q11 Development and Manufacture of Drug Substances is an ICH guideline that provides principles and expectations for the development and manufacturing of chemical and biotechnological drug substances within a quality-by-design framework.
All labels observed (1)
| Label | Occurrences |
|---|---|
| ICH Q11 Development and Manufacture of Drug Substances canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T5932397 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: ICH Q11 Development and Manufacture of Drug Substances Context triple: [ICH Q8 Pharmaceutical Development, relatedTo, ICH Q11 Development and Manufacture of Drug Substances]
-
A.
ICH Q8 Pharmaceutical Development
ICH Q8 Pharmaceutical Development is an international guideline that outlines a systematic, science- and risk-based approach to pharmaceutical product and process development, forming a core part of the ICH quality framework.
-
B.
ICH Q10 Pharmaceutical Quality System
ICH Q10 Pharmaceutical Quality System is an international guideline that establishes a comprehensive, lifecycle-based framework for pharmaceutical quality management to ensure consistent product quality and regulatory compliance.
-
C.
ICH Q9 Quality Risk Management
ICH Q9 Quality Risk Management is an international guideline that provides a systematic, science- and risk-based approach to identifying, evaluating, and controlling quality risks throughout the lifecycle of pharmaceutical products.
-
D.
Office of Pharmaceutical Quality
The Office of Pharmaceutical Quality is a U.S. Food and Drug Administration office responsible for ensuring the quality, safety, and consistency of human drugs throughout their lifecycle.
-
E.
Certificates of Suitability to the monographs of the European Pharmacopoeia
Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: ICH Q11 Development and Manufacture of Drug Substances Target entity description: ICH Q11 Development and Manufacture of Drug Substances is an ICH guideline that provides principles and expectations for the development and manufacturing of chemical and biotechnological drug substances within a quality-by-design framework.
-
A.
ICH Q8 Pharmaceutical Development
ICH Q8 Pharmaceutical Development is an international guideline that outlines a systematic, science- and risk-based approach to pharmaceutical product and process development, forming a core part of the ICH quality framework.
-
B.
ICH Q10 Pharmaceutical Quality System
ICH Q10 Pharmaceutical Quality System is an international guideline that establishes a comprehensive, lifecycle-based framework for pharmaceutical quality management to ensure consistent product quality and regulatory compliance.
-
C.
ICH Q9 Quality Risk Management
ICH Q9 Quality Risk Management is an international guideline that provides a systematic, science- and risk-based approach to identifying, evaluating, and controlling quality risks throughout the lifecycle of pharmaceutical products.
-
D.
Office of Pharmaceutical Quality
The Office of Pharmaceutical Quality is a U.S. Food and Drug Administration office responsible for ensuring the quality, safety, and consistency of human drugs throughout their lifecycle.
-
E.
Certificates of Suitability to the monographs of the European Pharmacopoeia
Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
ICH guideline
ⓘ
pharmaceutical quality guideline ⓘ |
| addresses |
control of starting materials
ⓘ
critical process parameters for drug substance manufacture ⓘ critical quality attributes of drug substances ⓘ design space for drug substance processes ⓘ lifecycle management of drug substance manufacturing processes ⓘ linkage of material attributes and process parameters to quality ⓘ risk management in drug substance development ⓘ selection of starting materials ⓘ |
| appliesTo |
biological drug substances
ⓘ
biotechnological drug substances ⓘ chemical drug substances ⓘ |
| basedOnConcept | quality by design ⓘ |
| concerns |
biotechnological/biological drug substances produced by cell culture or fermentation
ⓘ
small molecule drug substances ⓘ |
| documentType | harmonised tripartite guideline ⓘ |
| emphasizes |
linkage between development data and control strategy
ⓘ
systematic approach to development ⓘ use of prior knowledge and experimental data ⓘ |
| focusesOn |
development of drug substances
ⓘ
manufacture of drug substances ⓘ |
| fullTitle | ICH Harmonised Tripartite Guideline Q11: Development and Manufacture of Drug Substances NERFINISHED ⓘ |
| hasAbbreviation | ICH Q11 NERFINISHED ⓘ |
| includesGuidanceOn |
description of manufacturing process development
ⓘ
establishment of control strategy ⓘ information to be submitted in regulatory dossiers ⓘ process validation considerations for drug substances ⓘ scale-up and technology transfer considerations ⓘ |
| issuedBy | International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use NERFINISHED ⓘ |
| language | English ⓘ |
| objective |
to facilitate more flexible regulatory approaches to drug substance manufacturing
ⓘ
to promote scientific understanding of drug substance processes ⓘ to support consistent product quality over the lifecycle ⓘ |
| providesPrinciplesFor |
control strategy development
ⓘ
drug substance development ⓘ drug substance manufacturing process design ⓘ |
| regulatoryRegion |
European Union
NERFINISHED
ⓘ
ICH regions NERFINISHED ⓘ Japan NERFINISHED ⓘ United States NERFINISHED ⓘ |
| relatedTo |
ICH Q10 Pharmaceutical Quality System
NERFINISHED
ⓘ
ICH Q8 Pharmaceutical Development NERFINISHED ⓘ ICH Q9 Quality Risk Management NERFINISHED ⓘ |
| supportsImplementationOf |
ICH Q8 concepts for drug substances
ⓘ
pharmaceutical quality system for drug substances ⓘ quality risk management in development ⓘ |
| usedBy |
pharmaceutical industry
ⓘ
regulatory authorities in ICH regions ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: ICH Q11 Development and Manufacture of Drug Substances Description of subject: ICH Q11 Development and Manufacture of Drug Substances is an ICH guideline that provides principles and expectations for the development and manufacturing of chemical and biotechnological drug substances within a quality-by-design framework.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
ICH Q8 Pharmaceutical Development
→
relatedTo
→
ICH Q11 Development and Manufacture of Drug Substances
ⓘ
ICH Q9 Quality Risk Management
→
supports
→
ICH Q11 Development and Manufacture of Drug Substances
ⓘ